Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Rubin Lab
Explore this Website
Home
News
About Us
Research
Lab Team
Publications
Resources
Toggle Resources menu options
FISH
Profiler
Tracking Samples
Weill Cornell Medicine
Care
Discover
Teach
Home
News
About Us
Research
Lab Team
Publications
Resources
Home
Publications
Publications
Found 36 results
Author
Title
Type
Year
Filters:
First Letter Of Last Name
is
N
[Clear All Filters]
2013
Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al.
. 2013.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
.
Eur Urol. 63(5):920-6.
2012
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al.
. 2012.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
.
Nat Genet. 44(6):685-9.
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al.
. 2012.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
.
Nat Genet. 44(6):685-9.
Rickman DS, T Soong D, Moss B, Mosquera JMiguel, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V et al.
. 2012.
Oncogene-mediated alterations in chromatin conformation.
.
Proc Natl Acad Sci U S A. 109(23):9083-8.
2011
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discov. 1(6):487-95.
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discov. 1(6):487-95.
Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al.
. 2011.
Testing mutual exclusivity of ETS rearranged prostate cancer.
.
Lab Invest. 91(3):404-12.
2010
Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al.
. 2010.
Antibody-based detection of ERG rearrangement-positive prostate cancer.
.
Neoplasia. 12(7):590-8.
2009
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA
. 2009.
ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
.
Eur Urol. 56(2):275-86.
2005
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al.
. 2005.
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
.
Cancer Res. 65(13):5561-70.
Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA
. 2005.
Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.
.
Cancer Res. 65(13):5750-60.
« first
‹ previous
1
2
(current)